---

Highlights of September 2019

1. Strides Pharma acquires 70% stake in Switzerland based Fairmed Healthcare.
2. Biocon forays into China, signs pact with China Medical System (CMS) to sell 3 generic products.
3. Sun Pharma arm acquires remaining 3.04 % stake in PJSC Biosintez.
4. Lupin collaborates with Boehringer Ingelheim for novel oncology drug.
5. Cipla, Stempeutics ink licensing deal for Stempeucel-DFU to treat diabetic foot ulcer.
6. Biocon subsidiary acquires Chennai-based biological research facility from Pfizer Healthcare.
7. Lupin to sell its Japanese Injectables Business to Abu Dhabi based Neopharma Group.
8. Vertex plunks down US$950 Million for stem cell player Semma Therapeutics.
9. Moderna pens mRNA immunotherapy pact with Harvard.
10. CellaVision to acquire RAL Diagnostics.
11. Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine.

Updates at Aagami:

1. New Client Win: A UK Pharma with Marketed Products & Rich Pipeline with a focus on pediatric and other specialty medicinal products. They have appointed Aagami for Partnering support in 4 regions (US, Japan, India and South Korea).
2. Aagami starts accepting meetings for BIO-Europe 2019. If you too would like to meet us, please send us a meeting request on the partnering system or send us an email at godwyn@aagami.com
3. Aagami to represent multiple clients at BIO-Europe 2019.
4. Aagami to attend JPM and Biotech Showcase (January 2020). Meetings calendar will open first week of November 2019.